Handgrip weakness and mortality risk in COPD: a multicentre analysis

Handgrip strength is a simple measure of upper limb muscle function that is associated with mortality in the general population and in patients with COPD.\(^1\)\(^2\) Recently, normative values for handgrip strength have been proposed based on centile scores in >224 000 healthy adults between 39 and 73 years of age, adjusted for age, sex, height and measurement side.\(^3\)

As an illustration, in a typical 65-year-old male patient 5th and 10th centile of right handgrip strength range 18–28 kg and 20–30 kg, respectively, depending on the patient’s height. It is unclear whether the identification of handgrip weakness based on these centiles has prognostic value in addition to known prognostic parameters like FEV\(_1\), age, dyspnoea symptoms (combined in the validated ADO index\(^4\)) and body mass index (BMI).

Therefore, we performed an a posteriori analysis of prospectively collected multicentre data in patients with stable COPD, followed for a median of 3.9 years.\(^2\)\(^5\)\(^7\)

Handgrip strength was assessed using a Jamar Hydraulic Hand Dynamometer (JA Preston Corporation, Jackson, Michigan, USA) in all centres. Patients were seated in a chair with the elbow in 90° of flexion and touching the chest. In our analysis, both 5th and 10th centile of the normal population were used as cut-offs to define handgrip weakness. Patients were defined as weak if one side (left or right) was below the respective cut-off.

Descriptive data are reported as mean (SD) or median (25th–75th centile). Cox proportional hazard models were used to assess the relationship between handgrip weakness and mortality. HRs and 95% CI were calculated. Analyses were adjusted for ADO index (age, Modified Medical Research Council Dyspnea Scale (MMRC) and FEV\(_1\)) and BMI.

In total, 998 patients (age 67 (9) years; 72% male; FEV\(_1\) 53 (18) %pred; BMI 27 (5) kg/m²; MMRC 2 (1–3)) were included in the analysis. Handgrip force at baseline was 34 (11) kg on the right side and 31 (10) kg on the left side. Handgrip weakness was observed in 89 (9%) and 152 (15%) patients based on the 5th and 10th centile, respectively.

Median follow-up time was 47 months (range 24–60 months). During follow-up, 162 patients (16%) died. The proportion of patients with handgrip weakness was 26% (10th centile) and 15% (5th centile) in patients who died compared with 13% (5th centile) and 8% (10th centile) in survivors.

Characteristics and outcomes in different centres are provided in online supplementary table E1.

Unadjusted analysis reveals an association between handgrip weakness based on 10th centile and 5th centile cut-offs and mortality (HR 1.80 (1.25 to 2.54; p=0.002) and HR 1.71 (0.99 to 2.40; p=0.02), respectively).

After adjustment for ADO index and BMI, weakness based on 10th centile (HR 1.53 (1.07 to 2.12; p=0.02)) but not 5th centile (HR 1.50 (0.96 to 2.27; p=0.08)) remained significantly related to mortality (table 1A and B, respectively). Kaplan–Meier survival curves of the adjusted analysis can be found in online supplementary figure E1A, B.

Based on our findings, we propose to use the 10th centile of recently published normative values as a cut-off to define handgrip weakness in patients with COPD. The identification of handgrip weakness is easy, provides prognostic information in addition to known predictors as ADO index and BMI and may have a role in a quick multidimensional assessment of patients with COPD.

### Table 1

<table>
<thead>
<tr>
<th>HR (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>(A) Unadjusted</strong></td>
<td></td>
</tr>
<tr>
<td>Handgrip weakness (reference: &gt;C10)</td>
<td>1.80 (1.25 to 2.54)</td>
</tr>
<tr>
<td>Adjusted for ADO index and BMI</td>
<td></td>
</tr>
<tr>
<td>Handgrip weakness (reference: &gt;C10)</td>
<td>1.53 (1.07 to 2.12)</td>
</tr>
<tr>
<td>ADO index (continuous)</td>
<td>1.50 (1.36 to 1.66)</td>
</tr>
<tr>
<td>BMI (continuous)</td>
<td>0.92 (0.89 to 0.95)</td>
</tr>
<tr>
<td><strong>(B) Unadjusted</strong></td>
<td></td>
</tr>
<tr>
<td>Handgrip weakness (reference: &gt;C5)</td>
<td>1.71 (1.08 to 2.58)</td>
</tr>
<tr>
<td>Adjusted for ADO index and BMI</td>
<td></td>
</tr>
<tr>
<td>Handgrip weakness (reference: &gt;C5)</td>
<td>1.50 (0.96 to 2.27)</td>
</tr>
<tr>
<td>ADO index (continuous)</td>
<td>1.51 (1.37 to 1.67)</td>
</tr>
<tr>
<td>BMI (continuous)</td>
<td>0.92 (0.89 to 0.96)</td>
</tr>
</tbody>
</table>

ADO index, multidimensional disease index based on age, dyspnoea symptoms and FEV\(_1\) (range 0–10); BMI, body mass index; C10, centile 10; C5, 5th centile.
aspects of the work in ensuring that questions related
to the accuracy or integrity of any part of the work are
appropriately investigated and resolved.

Competing interests None declared.

Ethics approval Local ethics committees of different
centres (CFR published papers).

Provenance and peer review Not commissioned;
externally peer reviewed.

To cite Burtin C, ter Riet G, Puhan MA, et al. Thorax

Received 17 June 2015
Revised 10 September 2015
Accepted 6 October 2015
Published Online First 29 October 2015
doi:10.1136/thoraxjnl-2015-207451

REFERENCES
1 Leong DP, Teo KK, Rangarajan S, et al. Prognostic value
of grip strength: findings from the Prospective Urban Rural
2 Puhan MA, Siebeling L, Zoller M, et al. Simple
functional performance tests and mortality in COPD.
3 Spruit MA, Sillen MJ, Groenen MT, et al. New
normative values for handgrip strength: results from the
Expansion of the prognostic assessment of patients
with chronic obstructive pulmonary disease: the
updated BODE index and the ADO index. Lancet
effects of chronic obstructive pulmonary disease on
physical activity: a cross-sectional study. Am J Respir
6 Ramon MA, Gimeno-Santos E, Ferrer J, et al. Hospital
admissions and exercise capacity decline in patients
7 Waschki B, Kirsten A, Holz O, et al. Physical activity is
the strongest predictor of all-cause mortality in
patients with COPD: a prospective cohort study. Chest
2011;140:331–42.
Handgrip weakness and mortality risk in COPD: a multicentre analysis

Chris Burtin, Gerben ter Riet, Milo A Puhan, Benjamin Waschki, Judith Garcia-Aymerich, Victor Pinto-Plata, Bartolome Celli, Henrik Watz and Martijn A Spruit

Thorax 2016 71: 86-87 originally published online October 29, 2015
doi: 10.1136/thoraxjnl-2015-207451

Updated information and services can be found at:
http://thorax.bmj.com/content/71/1/86

These include:

Supplementary Material
Supplementary material can be found at:
http://thorax.bmj.com/content/suppl/2015/11/05/thoraxjnl-2015-207451.DC1

References
This article cites 7 articles, 2 of which you can access for free at:
http://thorax.bmj.com/content/71/1/86#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Epidemiologic studies (1829)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/